United Therapeutics (UTHR) Interest & Investment Income (2009 - 2026)

United Therapeutics has reported Interest & Investment Income for 16 years, with the latest figure at $41.8 million in Q1 2026.

• Quarterly Interest & Investment Income fell 18.2% year-over-year to $41.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $182.7 million (down 6.98% YoY) and the FY2025 annual result came in at $192.0 million, down 3.57% from the prior year.
• Interest & Investment Income declined to $41.8 million in Q1 2026 per UTHR's latest filing, from $43.2 million in the prior quarter.
• Over five years, Interest & Investment Income peaked at $53.8 million in Q1 2024 and troughed at $4.3 million in Q1 2022.
• A 5-year average of $37.7 million and a median of $45.3 million in 2023 frame the typical range for Interest & Investment Income.
• The sharpest annual moves came in 2023 and 2026: Interest & Investment Income surged 579.07% in 2023, then slipped 18.2% in 2026.
• Over 5 years, Interest & Investment Income stood at $20.8 million in 2022, then jumped by 145.19% to $51.0 million in 2023, then fell by 3.33% to $49.3 million in 2024, then dropped by 12.37% to $43.2 million in 2025, then dropped by 3.24% to $41.8 million in 2026.
• According to Business Quant data, Interest & Investment Income over the past three periods registered $41.8 million, $43.2 million, and $46.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.